Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Sunday. The brokerage set a “hold” rating on the stock.

Can-Fite BioPharma Stock Down 7.9 %

NYSE:CANF opened at $2.10 on Friday. The firm’s fifty day simple moving average is $2.16 and its 200 day simple moving average is $2.14. The stock has a market cap of $7.43 million, a P/E ratio of -1.17 and a beta of 1.53. Can-Fite BioPharma has a twelve month low of $1.55 and a twelve month high of $3.33.

Can-Fite BioPharma (NYSE:CANF) last announced its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. On average, analysts expect that Can-Fite BioPharma will post -0.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CANF. Schechter Investment Advisors LLC purchased a new stake in Can-Fite BioPharma in the fourth quarter worth $44,000. Virtu Financial LLC purchased a new position in Can-Fite BioPharma in the second quarter worth about $52,000. Finally, Armistice Capital LLC bought a new position in Can-Fite BioPharma in the 4th quarter valued at approximately $340,000. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.